Collegium Pharmaceutical shares tumbled 13.2% in pre-open trading after the specialty biopharmaceutical company released its second-quarter 2026 financials ahead of the market and simultaneously reduced its full-year revenue forecast.
The company recorded net revenues of $199.9 million for the quarter, representing a 6.3% increase from the same period a year earlier. That top-line figure, however, came in just under the roughly $201.2 to $201.4 million range analysts had expected. More notable to investors was the revised full-year revenue guidance, the midpoint of which landed about 3.4% below prior Street estimates.
On the profitability front, Collegium exceeded expectations. Adjusted earnings per share were $1.92, above consensus of about $1.72, and adjusted EBITDA was $113.8 million, also outperforming forecasts. Despite those upside surprises on the earnings line, the market reaction was dominated by revenue and guidance developments.
The company provided additional detail on product performance. The pain portfolio - which comprises BELBUCA, Xtampza ER, and the Nucynta franchise - generated quarterly net revenues of $140.9 million. That segment continues to face pressure from generic competition, which has weighed on its sales. By contrast, JORNAY PM posted strong growth, with sales rising 41% year-over-year to $46.1 million. Separately, AZSTARYS, acquired in May in a $650 million deal, contributed $12.9 million for the partial quarter following the closing of that transaction.
Market context was limited. The NASDAQ composite was modestly lower on the day, offering a slightly unfavorable background for growth-oriented healthcare names, while the S&P 500 was essentially unchanged. The disparity between the broad indexes and Collegium's pre-market decline suggests the move was driven largely by company-specific factors rather than a broader sector or macro development.
Investors reacted to the combination of a marginal revenue miss, a downward revision to full-year revenue expectations, and ongoing concerns about the durability of the pain product franchise. The sell-off pushed the stock toward its 52-week low of $30.13, effectively wiping out the appreciation that had accumulated since the AZSTARYS acquisition was announced.
Summary
Collegium reported Q2 net revenue of $199.9 million, a 6.3% increase year-over-year, but missed analyst revenue estimates by roughly $1.3 to $1.5 million. The company beat on adjusted EPS and adjusted EBITDA, but a trimmed full-year revenue outlook with a midpoint about 3.4% below prior Street expectations triggered a sharp pre-market stock decline of 13.2%.